250 / 1498
Conclusions
•
Risk of hematological SMNs has decreased over time
•
Risk solid SMNs does not appear to decrease in
patients treated before 2000, potentially due to
changes in chemotherapy regimens and more breast
cancer screening.
•
Awareness of increased SMN risk remains crucial for
HL survivors.
Schaapveld et al , submitted